Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project

Macular Diseases

Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study

Br J Ophthalmol

Ruiz-Medrano J, Udaondo Mirete P, Fernández-Jiménez M, Asencio-Duran M, Fernández-Vigo JI, Medina-Baena M, Flores-Moreno I, Pareja-Esteban J, Touhami S, Giocanti-Aurégan A, Cicinelli MV, Loewenstein A, Ruiz-Moreno JM

doi: 10.1136/bjo-2024-325665

Macular DiseasesFurther Publications

Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence

BMC Ophthalmol

Owlya N, Barbosa M, Bartolomeo N, Pannatier-Schuetz Y, Nascimbeni AC, Castro DG, Barry MP, Ambresin A

doi: 10.1186/s12886-026-04651-w

Macular DiseasesRetinal Diseases

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Sci Rep

Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST

doi: 10.1038/s41598-025-20300-6

Macular Diseases

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

BMJ Open Ophthalmol

Saad A, Plasencia C, Garweg J, Pfister IB, Munk MR, Eandi CM, Zweifel SA, Grimaldi G, Bartolomeo N, Stillenmunkes R, Schild C, Cattaneo J, Gabathuler F, Menghini M, Ambersin A, Froehlich J, Artemiev D, Weinberger A, Mohamed H, Somfai GM, Hatz K

doi: 10.1136/bmjophth-2025-002467

Macular Diseases

Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis

JAMA Ophthalmol

Khan MA, Hill L, Stoilov I, Haller JA

doi: 10.1001/jamaophthalmol.2024.6371

CataractsDry Eye Disease

Risk factors and nomogram-based prediction of dry eye disease following intraocular lens implantation in cataract patients

BMC Ophthalmol

Xu HY, Lang SK, Jiang H

doi: 10.1186/s12886-025-04369-1

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Macular DiseasesSurgery and InterventionCataracts

Effect of combined mature cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema

BMC Ophthalmol

Shen Y, Zhu X, Li AQ, Ji M, Guan HJ

doi: 10.1186/s12886-025-04264-9

Macular Diseases

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration

BMC Ophthalmol

Menghini M, Grimaldi G, Paris A, Bachmann LM, Schmid MK

doi: 10.1186/s12886-025-04463-4

Related content

Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study

Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis

Risk factors and nomogram-based prediction of dry eye disease following intraocular lens implantation in cataract patients

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

Effect of combined mature cataract surgery and intravitreal ranibizumab injection in eyes with pre-existing diabetic macular edema

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration